Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
63 participants
OBSERVATIONAL
2017-06-27
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Biomarker During Liver Surgery
NCT02102971
Harms of Hepatocellular Carcinoma Surveillance
NCT03756051
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
NCT00629421
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
NCT06950788
Longitudinal Outcomes in Hepatic Resection
NCT02997098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The incidence of cirrhosis is increasing as alcoholic liver disease overtakes hepatitis as the cause of cirrhosis although it will likely stabilize as Hepatitis C treatment makes its way through the population. However, liver disease continues to have a large impact on morbidity and mortality with a prevalence of approximately 4.5 million people diagnosed with liver disease with an incidence of 1.8% per year and 12.8 deaths per 100,000 people. The cost of treating cirrhosis ranges from $14 million to $2 billion dollars depending on the etiology of the disease. The large cost is driven by multiple hospitalizations, surgical procedures, rehabilitation/nursing home, and other factors.
For surgeons, cirrhotic patients represent an especially high-risk patient population. In the past, many surgeons were hesitant to offer definitive surgeries for symptomatic cholelithiasis, hernias, or cancer surgeries. Historically these patients had a high risk of mortality with competing causes of mortality driven by liver cirrhosis as well as other issues. Hence, it was thought that these patients should only be operated on in emergent cases unless it precluded them from being transplant eligible. For example, Garrison, et al. noted in 1984 that patients who underwent exploratory laparotomy with either a Child B and C had a 31% and 76% mortality, respectively. Furthermore, this was not unique to that group as another group in 1997 showed surgeries like hernia procedures, cholecystectomy, and other procedures had mortality rates of up to 82% for Child C cirrhotics. As general post-surgical care and critical care have improved, contemporary studies show that mortality although decreased still is significant. A prospective study looking at cirrhotic patients who underwent an umbilical hernia for 30 patients had a mortality of 6%. Moreover, a retrospective analysis of a prospectively maintained database from the American College of Surgeons National Surgical Quality Improvement Program revealed that in a series of 390 pts undergoing umbilical hernia repair there was a 5.1% mortality and 13.1% morbidity in comparison to 0.1 and 3.9% on non-cirrhotic patients, respectively.
There are few papers that look at the drivers of morbidity, mortality, and complications among this population and none looking at more than 30 days post-operative re-admissions, morbidity, or mortality. Furthermore, there is no literature on how elective or emergent surgery may facilitate a longer survival so that patients may still be alive and eligible to receive their liver, the ultimate treatment for liver cirrhosis. Hence, the investigator's tertiary center experience was evaluated focusing on pre-operative, intraoperative, and postoperative factors that may explain the drivers of morbidity and mortality in cirrhotics undergoing elective and emergent surgery. The investigators will also study at how many patients after their index procedure survived to receive their liver transplant. Hence, the investigator's surgical, single-center experience at a tertiary hospital with the largest referral center in the area for liver transplant candidates for any cirrhotics requiring surgery either emergent (\<24 hours since admission), urgent (same admission but \> 24 hrs), or elective (patient coming from outpatient setting for planned surgery). The investigators hypothesize, that although the risk is high for patients undergoing surgery, it currently is much lower than historically reported, which may make more patients eligible for transplant and prevent complications that may lead to death for the transplant eligible patients, and may reveal associations that can lead to good outcomes in this high-risk population.
Materials and Methods
The investigator's institutional review board approved this study and data were collected in a retrospective fashion. Initially, a query was done looking at all participants with cirrhosis who underwent any procedure done by the principal investigator. After this, a chart review was done looking at all the participants with a diagnosis of cirrhosis via manual chart review. The index procedure, as well as any re-operation done, were included and all performed by the surgeon who is the principal investigator. Furthermore, pre-operative data that was collected included medications used to treat cirrhosis, etiology of cirrhosis, biological Na-MELD/ Child's classification, whether a transjugular intrahepatic portosystemic shunt was performed, the incidence of esophageal varices/ ascites, pre-operative drainage of ascites or placement of a drain as well as cases of refractory ascites.
Furthermore, intraoperative data were obtained from the anesthesia records regarding estimated blood loss, crystalloid/ colloid administered, blood products administered, any episodes of hypotension, and the use of vasopressors. Post-operative data collected included any complications, blood products administered, the use of colloids, and finally the date of discharge. The participants were tracked for over a year and any cases of re-admission were noted from the charts and the causes of re-admission were noted for further analysis.
Data was collected in a de-identified fashion. Comparisons were done via Student T-tests when applicable. Logistic regression was done to identify factors associated with a given outcome including morbidity and mortality with a limit of 3 factors chosen in a univariable model and multivariable model given the low number of cases. Kaplan Meier curves were done to analyze the time to transplant after elective surgery to analyze whether elective surgery may increase the life span of cirrhotics who undergo surgery and stratifying by different risk factors to predict who may need a transplant sooner after elective surgery. Data were analyzed via SPSS 26.0.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cirrhosis
Patients with cirrhosis undergoing urgent and elective surgery
Elective surgery
Patient undergoing elective or urgent surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elective surgery
Patient undergoing elective or urgent surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a known, symptomatic and documented pre-operative history of cirrhosis
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danny Lascano
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Danny Lascano
Research Resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Veillette, MD
Role: PRINCIPAL_INVESTIGATOR
Westchester Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Westchester Medical Center
Valhalla, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y). 2011 Oct;7(10):661-71.
Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg. 1984 Jun;199(6):648-55. doi: 10.1097/00000658-198406000-00003.
Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery. 1997 Oct;122(4):730-5; discussion 735-6. doi: 10.1016/s0039-6060(97)90080-5.
Eker HH, van Ramshorst GH, de Goede B, Tilanus HW, Metselaar HJ, de Man RA, Lange JF, Kazemier G. A prospective study on elective umbilical hernia repair in patients with liver cirrhosis and ascites. Surgery. 2011 Sep;150(3):542-6. doi: 10.1016/j.surg.2011.02.026. Epub 2011 May 31.
Cho SW, Bhayani N, Newell P, Cassera MA, Hammill CW, Wolf RF, Hansen PD. Umbilical hernia repair in patients with signs of portal hypertension: surgical outcome and predictors of mortality. Arch Surg. 2012 Sep;147(9):864-9. doi: 10.1001/archsurg.2012.1663.
Related Links
Access external resources that provide additional context or updates about the study.
Data regarding incidence/ prevalence of cirrhosis in the US
Kochanek K.K. MSL, Xu J., Arias E. Deaths: Final Data for 2017. National Vital Statistics Reports, \[Internet\]. 2017; 68(9):\[77 p.\]. Available from: https://http://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68\_09-508.pdf
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L12-124
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.